Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × Neuroectodermal Tumors × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Completed 3 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 323 Breast Neoplasms 312 Colorectal Neoplasms 207 Stomach Neoplasms 183 Carcinoma, Hepatocellular 133 Neoplasms 103 Lung Neoplasms 100 Pancreatic Neoplasms 91 Prostatic Neoplasms 86 Rectal Neoplasms 82 Ovarian Neoplasms 82 Recurrence 81 Neoplasm Metastasis 79 Nasopharyngeal Carcinoma 77 Esophageal Squamous Cell Carcinoma 70 Lymphoma, Large B-Cell, Diffuse 69 Leukemia, Myeloid, Acute 68 Esophageal Neoplasms 67 Melanoma 64 Lymphoma 62 Head and Neck Neoplasms 61 Brain Neoplasms 61 Small Cell Lung Carcinoma 60 Squamous Cell Carcinoma of Head and Neck 58 Multiple Myeloma 58 Sarcoma 56 Uterine Cervical Neoplasms 54 Carcinoma, Renal Cell 54 Triple Negative Breast Neoplasms 49 Lymphoma, Non-Hodgkin 47

Interventions

Vorinostat 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡